Menu
Back to User profile » Dr Changli Wu
Papers published by Dr Changli Wu:
Polymorphism in IGFBP3 gene is associated with prostate cancer risk: an updated meta-analysis
Qie YK, Nian XW, Liu XS, Hu HL, Zhang CW, Xie LG, Han RF, Wu CL, Xu Y
OncoTargets and Therapy 2016, 9:4163-4171
Published Date: 7 July 2016
The value of extensive transurethral resection in the diagnosis and treatment of nonmuscle invasive bladder cancer with respect to recurrence at the first follow-up cystoscopy
Qie Y, Hu H, Tian D, Zhang Y, Xie L, Xu Y, Wu C
OncoTargets and Therapy 2016, 9:2019-2025
Published Date: 5 April 2016
The evaluation of the association between the metabolic syndrome and tumor grade and stage of bladder cancer in a Chinese population
Sha N, Xu H, Chen T, Tian DW, Xie WQ, Xie LG, Zhang Y, Xing C, Liu XT, Shen ZH, Wu ZL, Hu HL, Wu CL
OncoTargets and Therapy 2016, 9:1175-1179
Published Date: 7 March 2016
Intravenous chemotherapy combined with intravesical chemotherapy to treat T1G3 bladder urothelial carcinoma after transurethral resection of bladder tumor: results of a retrospective study
Zhang Y, Xie LG, Chen T, Xie WQ, Wu ZL, Xu H, Xing C, Sha N, Shen ZH, Qie YK, Liu XT, Hu HL, Wu CL
OncoTargets and Therapy 2016, 9:605-611
Published Date: 28 January 2016
Association between MDM2 SNP309 T>G polymorphism and the risk of bladder cancer: new data in a Chinese population and an updated meta-analysis
Xie LG, Sun Y, Chen T, Tian DW, Li YJ, Zhang Y, Ding N, Shen ZH, Xu H, Nian XW, Sha N, Han RF, Hu HL, Wu CL
OncoTargets and Therapy 2015, 8:3679-3690
Published Date: 7 December 2015
Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection
Sha N, Xie L, Chen T, Xing C, Liu X, Zhang Y, Shen Z, Xu H, Wu Z, Hu H, Wu C
OncoTargets and Therapy 2015, 8:3401-3406
Published Date: 18 November 2015